CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
टिप्पणियां
आपके खाते में कोई अवतार नहीं है
टिप्पणी पोस्ट करने के साथ आगे बढ़ने के लिए, कृपया अस्थायी अवतार का चयन करें:
Confirm
कुछ गड़बड़ हो गयी है। कृपया पुन: प्रयास करें।
Or
Y8 खाते पर अपलोड करें
रद्द करें